Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Heterologous matrix metalloproteinase gene promoter activity allows in vivo real-time imaging of bleomycin-induced lung fibrosis in transiently transgenized mice

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Stellari, Fabio Franco; Ruscitti, Francesca; Pompilio, Daniela; Ravanetti, Francesca; Tebaldi, Giulia; Macchi, Francesca; Verna, Andrea Elizabeth; Villetti, Gino; Donofrio, Gaetano
    • بيانات النشر:
      Frontiers Research Foundation
    • الموضوع:
      2017
    • Collection:
      Università di Parma: CINECA IRIS
    • نبذة مختصرة :
      Idiopathic pulmonary fibrosis is a very common interstitial lung disease derived from chronic inflammatory insults, characterized by massive scar tissue deposition that causes the progressive loss of lung function and subsequent death for respiratory failure. Bleomycin is used as the standard agent to induce experimental pulmonary fibrosis in animal models for the study of its pathogenesis. However, to visualize the establishment of lung fibrosis after treatment, the animal sacrifice is necessary. Thus, the aim of this study was to avoid this limitation by using an innovative approach based on a double bleomycin treatment protocol, along with the in vivo images analysis of bleomycin-treated mice. A reporter gene construct, containing the luciferase open reading frame under the matrix metalloproteinase-1 promoter control region, was tested on double bleomycin-treated mice to investigate, in real time, the correlation between bleomycin treatment, inflammation, tissue remodeling and fibrosis. Bioluminescence emitted by the lungs of bleomycin-treated mice, corroborated by fluorescent molecular tomography, successfully allowed real time monitoring of fibrosis establishment. The reporter gene technology experienced in this work could represent an advanced functional approach for real time non-invasive assessment of disease evolution during therapy, in a reliable and translational living animal model.
    • Relation:
      info:eu-repo/semantics/altIdentifier/wos/WOS:000395016500001; volume:8; issue:MAR; firstpage:199; journal:FRONTIERS IN IMMUNOLOGY; http://hdl.handle.net/11381/2823329; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85017104895; http://journal.frontiersin.org/article/10.3389/fimmu.2017.00199/full
    • الرقم المعرف:
      10.3389/fimmu.2017.00199
    • الرقم المعرف:
      10.3389/fimmu.2017.00199/full
    • الدخول الالكتروني :
      http://hdl.handle.net/11381/2823329
      https://doi.org/10.3389/fimmu.2017.00199
      http://journal.frontiersin.org/article/10.3389/fimmu.2017.00199/full
    • Rights:
      info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.54E55FCC